STORM Therapeutics and AlidaBio Announce Strategic Collaboration to Accelerate Development of Cancer Therapies Targeting RNA Modifications

/in

8 January 2026, Cambridge, UK, and San Diego, US: STORM Therapeutics Ltd. (STORM), the clinical stage company pioneering cellular reprogramming through RNA modifications to treat disease, today announced a strategic collaboration with Alida Biosciences Inc. (AlidaBio), a company at the forefront of epitranscriptomics and RNA modification analysis. STORM will utilize AlidaBio’s advanced EpiPlex® and EpiScout® next-generation sequencing […]

Read more

ViCentra Expands Financing to $98 Million to Accelerate European Commercialization and Ready Next Generation Kaleido Insulin Patch Pump System for U.S. Access

/in

Secures an additional $13 million, bringing the total to $98 million with new investments from ROM Utrecht Region and a consortium of Dutch investors, including Venturing Tech, plus increased support from Innovation Industries Strengthens manufacturing scale-up and commercial operations in Germany, the Netherlands, and France, and advances U.S. market preparation Validates ViCentra’s strategy and team, […]

Read more

TECregen Raises CHF 10 Million in Seed Financing and Appoints Dr. Bo Rode Hansen as Chairman

/in

TECregen Raises CHF 10 Million in Seed Financing and Appoints Dr. Bo Rode Hansen as Chairman Groundbreaking thymus-rejuvenating biologics are designed to restore immune function and promote lasting immune health throughout all stages of life Basel, Switzerland, January 8, 2026 – TECregen, a biotechnology company pioneering thymus regeneration, today announced the successful completion of a […]

Read more

Lonza’s Synaffix and Sidewinder Therapeutics Announce Multi-Target License Agreement to Advance Development of Next‑Generation Bispecific ADCs

/in

Multi-target license agreement grants Sidewinder access to Lonza’s clinically validated ADC platform Sidewinder’s pipeline of precision bispecific ADCs combined with Lonza’s clinically validated ADC platform will enable the development of first-in-class bispecific ADCs with enhanced tumor-cell internalization to treat solid tumor indications Amsterdam, The Netherlands, and San Diego, CA, 7 January 2026 — Synaffix B.V. […]

Read more

Nucleome Therapeutics nominates first preclinical development candidate

/in

First-in-class monoclonal antibody agonist programme for inflammation resolution with broad applicability across major chronic inflammatory diseases Evolution of Nucleome’s non-coding genetics platform reveals further groundbreaking insights into disease areas of high unmet need Oxford, UK, 07 January 2026 – Nucleome Therapeutics (‘Nucleome’ or ‘the Company’), a company tackling the molecular causes of inflammatory diseases through […]

Read more
© Optimum Strategic Communications.